Lancashire and South Cumbria
Formulary
Formulary
8 Malignant disease and immunosuppression
The majority of systemic anti-cancer therapies are not listed in this formulary as they are included in either the Lancashire and South Cumbria Cancer Alliance SACT protocols or the Cancer Drugs Fund list, produced by NHSE. |
08-02-02 Corticosteroids and other immunosuppressants
| Avacopan Tavneos® |
|
Formulary
|
Hard Capsules, 10mg |
 NICE TA825: Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis |
|
| Ciclosporin Neoral® |
|
Formulary
|
Capsules 25mg, 50mg, 100mg For use in other indications see sections 01.05.03, 10.01.03, and 11.11. |
 LSCMMG: Shared care guideline: Ciclosporin |
|
|
| Pegcetacoplan Aspaveli® |
|
Formulary
|
Solution for infusion. Each 20 mL vial contains 1 080 mg of pegcetacoplan. |
|
NICE TA778: Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria |
|
|
| Sirolimus Rapamune® |
|
Formulary
|
| Tablets 500micrograms, 1mg, 2mg The 500 microgram tablet is not bioequivalent to the 1 mg and 2 mg tablets. Multiples of 500 microgram tablets should not be used as a substitute for other tablet strengths. |
|
MHRA: Sirolimus: different immunoassays for therapeutic drug monitoringrisk of incorrect dose adjustment NICE TA481: Immunosuppressive therapy for kidney transplant in adults NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
|
|
| Tacrolimus |
|
Formulary
|
Brand name prescribing essential See section 13.05.03 for use in dermatology. |
|
LSCMMG: Position Statement Prescribing of Oral Tacrolimus MHRA: Oral tacrolimus products: reminder to prescribe and dispense by brand name only NICE TA481: Immunosuppressive therapy for kidney transplant in adults NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
|
|
| Voclosporin Lupkynis® |
|
Formulary
|
Capsules 7.9mg
|
|
NICE TA882: Voclosporin with mycophenolate mofetil for treating lupus nephritis |
|
|
NICE TA882 Voclosporin with mycophenolate mofetil for treating lupus nephritisLinks
- CAS letter: Oral tacrolimus products should be prescribed and dispensed by brand name to avoid the risk of medication errors
- CAS letter: Oral tacrolimus products should be prescribed and dispensed by brand name to avoid the risk of medication errors
- LSC Breast Chemotherapy Protocols
- LSCMMG: Position Statement Prescribing of Oral Tacrolimus
- LSCMMG: Shared care guideline: Ciclosporin
- MHRA Drug safety Update Jan 2018: Daclizumab (Zinbryta) and risk of severe liver injury: new restrictions to use and strengthened liver monitoring
- MHRA Drug Safety Update July 2017: Daclizumab (Zinbryta) and risk of severe liver injury: initiation in multiple sclerosis now restricted, promptly review patients already on treatment
- MHRA Drug Safety Update March 2018: Daclizumab (Zinbryta): suspension and recall for safety reasons; review patients as soon as possible and start alternative therapy
- MHRA Drug Safety Update Nov 2017: Oral tacrolimus products: reminder to prescribe and dispense by brand name only
- MHRA: Oral tacrolimus products: reminder to prescribe and dispense by brand name only
- MHRA: Sirolimus: different immunoassays for therapeutic drug monitoringrisk of incorrect dose adjustment
- NHSE: National Cancer Drugs Fund list
- NICE NG122 : Lung cancer: diagnosis and management
- NICE NG224: Melanoma: assessment and management
- NICE NG47: Haematological cancers: improving outcomes
- NICE NG52: Non-Hodgkins lymphoma: diagnosis and management
- NICE TA441: Daclizumab for treating relapsingremitting multiple sclerosis
- NICE TA481: Immunosuppressive therapy for kidney transplant in adults
- NICE TA481: Immunosuppressive therapy for kidney transplant in adults
- NICE TA481: Immunosuppressive therapy for kidney transplant in adults
- NICE TA481: Immunosuppressive therapy for kidney transplant in adults
- NICE TA481: Immunosuppressive therapy for kidney transplant in adults
- NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
- NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
- NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
- NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
- NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
- NICE TA706: Ozanimod for treating relapsingremitting multiple sclerosis
- NICE TA706: Ozanimod for treating relapsingremitting multiple sclerosis
- NICE TA778: Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria
- NICE TA778: Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria
- NICE TA794 : Diroximel fumarate for treating relapsingremitting multiple sclerosis
- NICE TA794: Diroximel fumarate for treating relapsingremitting multiple sclerosis
- NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease
- NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease
- NICE TA825: Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis
- NICE TA825: Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis
- NICE TA828: Ozanimod for treating moderately to severely active ulcerative colitis
- NICE TA828:Ozanimod for treating moderately to severely active ulcerative colitis
- NICE TA882: Voclosporin with mycophenolate mofetil for treating lupus nephritis
- NICE TA882: Voclosporin with mycophenolate mofetil for treating lupus nephritis
- NICE TA99: Immunosuppressive therapy for renal transplantation in children and adolescents